More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.56B
EPS
2.3
P/E ratio
--
Price to sales
63.09
Dividend yield
--
Beta
1.798163
Previous close
$14.73
Today's open
$14.80
Day's range
$14.11 - $14.87
52 week range
$12.43 - $28.23
show more
CEO
Arthur T. Sands
Employees
317
Headquarters
Brisbane, CA
Exchange
NASDAQ Global Market
Shares outstanding
109249814
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Nurix Therapeutics, Inc. (NRIX) Presents at UBS Global Biopharma Conference 2026 Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
Physician-scientist and oncology leader brings more than two decades of experience in academic medicine, global clinical development and regulatory submissions Physician-scientist and oncology leader brings more than two decades of experience in academic medicine, global clinical development and regulatory submissions
GlobeNewsWire • Nov 11, 2026

Nurix Therapeutics to Participate in Upcoming Investor Conferences
BRISBANE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Company management will participate in fireside chats at the following investor conferences: UBS Global Biopharma Conference Tuesday, November 17, 2026, at 2:40 p.m.
GlobeNewsWire • Nov 10, 2026

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
BRISBANE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that new and updated clinical data from its ongoing Phase 1a/1b study evaluating bexobrutideg (NX-5948), the Company's investigational oral Bruton's tyrosine kinase (BTK) degrader, will be presented in a poster session at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 12-15, 2026 in New Orleans, Louisiana.
GlobeNewsWire • Nov 5, 2026

Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema Development
Shares of Nurix Therapeutics crashed Wednesday after Sanofi unexpectedly scrapped an experimental eczema drug that two were codeveloping.
Investors Business Daily • Nov 4, 2026

Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR448272
BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program.
GlobeNewsWire • Nov 3, 2026

Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways
Nurix Therapeutics is maintained at "Strong Buy" due to pivotal progress with bexobrutideg, robust partnerships, and strong financials. The company initiated the phase 3 DAYBreak CLL-306 study, aiming to demonstrate bexobrutideg's superiority over JAYPIRCA in relapsed/refractory CLL/SLL. Potential Accelerated Approval for bexobrutideg in 3rd-line+ r/r CLL/SLL is supported by promising phase 1/2 data and ongoing pivotal trials.
Seeking Alpha • Oct 14, 2026

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL
GlobeNewsWire • Oct 12, 2026

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
Nurix Therapeutics, Inc. (NRIX) came out with quarterly earnings of $4.73 per share, beating the Zacks Consensus Estimate of a loss of $0.56 per share. This compares to a loss of $1.03 per share a year ago.
Zacks Investment Research • Oct 12, 2026

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation of bexobrutideg given in combination with venetoclax and selected antibodies in the Roche portfolio of B-cell malignancy therapies BRISBANE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that the first patient has been enrolled in the Phase 1b/2 NX-5948-203 study evaluating bexobrutideg, an investigational oral Bruton's tyrosine kinase (BTK) degrader, in combination with venetoclax, a standard-of-care therapy for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
GlobeNewsWire • Oct 7, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Nurix Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.